Outlook Therapeutics has re-submitted its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) ...
EST Outlook Therapeutics (OTLK) files to sell 7.07M shares of common stock for holdersDiscover the Best Stocks and Maximize Your ...
We remain committed to bringing an ophthalmic bevacizumab to market in the United States and providing retina patients suffering from wet AMD with a much needed treatment option that has the potential ...
Outlook Therapeutics (NASDAQ:OTLK – Get Free Report) had its price target reduced by research analysts at Ascendiant Capital Markets from $33.00 to $24.00 in a research note issued to investors on ...
On-demand video webcast now available here ISELIN, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval ...
Outlook Therapeutics, Inc. has announced the appointment of Faisal G. Sukhtian as Chairman of the Board of Directors, taking over from Randy Thurman, who will remain as Lead Independent Director.
ISELIN, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United ...
ISELIN, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United ...
16h
Hosted on MSNJP Morgan Downgrades Intellia Therapeutics (NTLA)Fintel reports that on February 28, 2025, JP Morgan downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from ...
Research analysts at HC Wainwright lowered their Q1 2025 earnings estimates for shares of Fulcrum Therapeutics in a report released on Wednesday, February 26th. HC Wainwright analyst A. Fein now ...
1d
Hosted on MSNHC Wainwright & Co. Downgrades LAVA Therapeutics N.V. (LVTX)Fintel reports that on February 27, 2025, HC Wainwright & Co. downgraded their outlook for LAVA Therapeutics N.V.
ISELIN, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results